Last reviewed · How we verify
CKD-825
CKD-825 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
CKD-825 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Hormone receptor-positive, HER2-negative breast cancer.
At a glance
| Generic name | CKD-825 |
|---|---|
| Also known as | Test |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a SERD, CKD-825 binds to the estrogen receptor with high affinity and promotes its proteasomal degradation, eliminating both ligand-dependent and ligand-independent signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than partial antagonism, potentially overcoming resistance mechanisms in estrogen receptor-positive breast cancer.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer
Common side effects
- Hot flashes
- Fatigue
- Nausea
- Vaginal dryness
Key clinical trials
- A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-825 CI brief — competitive landscape report
- CKD-825 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI